Biomaterials are regularly used in various types of artificial tissues and organs, such as
oxygenators, plasmapheresis equipment, hemodialysers, catheters, prostheses, stents …

There is a growing awareness that complement plays an integral role in human physiology
and disease, transcending its traditional perception as an accessory system for pathogen …

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in
industrialized nations, affecting 30–50 million people worldwide. The earliest clinical …

Complement C3 activation contributes to COVID-19 pathology, and C3 targeting has
emerged as a promising therapeutic strategy. We provide interim data from ITHACA, the first …

Complement has been implicated in liver repair after toxic injury. Here, we demonstrate that
complement components are essential for liver regeneration, and mediate their effect by …

Despite the growing recognition of the complement system as a major contributor to a variety
of clinical conditions, the therapeutic arsenal has remained scarce. The introduction of an …

Within a short few years, the number of complement inhibitors that are either approved for
therapeutic application or evaluated in late‐stage clinical trials has expanded remarkably …

With the addition of the compstatin-based complement C3 inhibitor pegcetacoplan, another
class of complement targeted therapeutics have recently been approved. Moreover …

Therapeutic modulation of the human complement system is considered a promising
approach for treating a number of pathological conditions. Owing to its central position in the …

The FDA approval of pegcetacoplan (Empaveli), a PEGylated compstatin-based C3
therapeutic, as a new treatment for paroxysmal nocturnal hemoglobinuria (PNH) marks a …